JP2011507933A5 - - Google Patents

Download PDF

Info

Publication number
JP2011507933A5
JP2011507933A5 JP2010540130A JP2010540130A JP2011507933A5 JP 2011507933 A5 JP2011507933 A5 JP 2011507933A5 JP 2010540130 A JP2010540130 A JP 2010540130A JP 2010540130 A JP2010540130 A JP 2010540130A JP 2011507933 A5 JP2011507933 A5 JP 2011507933A5
Authority
JP
Japan
Prior art keywords
antigen
targeting agent
use according
cell
bound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010540130A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011507933A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/068268 external-priority patent/WO2009080831A1/en
Publication of JP2011507933A publication Critical patent/JP2011507933A/ja
Publication of JP2011507933A5 publication Critical patent/JP2011507933A5/ja
Pending legal-status Critical Current

Links

JP2010540130A 2007-12-26 2008-12-23 免疫複合体の細胞傷害性副作用の低減及び有効性の改善方法 Pending JP2011507933A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1661307P 2007-12-26 2007-12-26
US1663007P 2007-12-26 2007-12-26
PCT/EP2008/068268 WO2009080831A1 (en) 2007-12-26 2008-12-23 Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014241327A Division JP2015038158A (ja) 2007-12-26 2014-11-28 免疫複合体の細胞傷害性副作用の低減及び有効性の改善方法

Publications (2)

Publication Number Publication Date
JP2011507933A JP2011507933A (ja) 2011-03-10
JP2011507933A5 true JP2011507933A5 (enExample) 2012-02-16

Family

ID=40459778

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010540130A Pending JP2011507933A (ja) 2007-12-26 2008-12-23 免疫複合体の細胞傷害性副作用の低減及び有効性の改善方法
JP2014241327A Pending JP2015038158A (ja) 2007-12-26 2014-11-28 免疫複合体の細胞傷害性副作用の低減及び有効性の改善方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014241327A Pending JP2015038158A (ja) 2007-12-26 2014-11-28 免疫複合体の細胞傷害性副作用の低減及び有効性の改善方法

Country Status (6)

Country Link
US (1) US9011864B2 (enExample)
EP (1) EP2238169A1 (enExample)
JP (2) JP2011507933A (enExample)
AR (1) AR069979A1 (enExample)
TW (1) TWI524897B (enExample)
WO (1) WO2009080831A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004224925C1 (en) * 2004-08-30 2011-07-21 Biotest Ag Immunoconjugates targeting syndecan-1 expressing cells and use thereof
CN101952315B (zh) * 2007-12-26 2015-04-01 生物测试股份公司 靶向cd138的试剂及其应用
RU2547939C2 (ru) * 2007-12-26 2015-04-10 Биотест Аг Иммуноконъюгаты, направленные на cd138, и их применение
PL2240516T3 (pl) * 2007-12-26 2015-12-31 Biotest Ag Sposoby i środki do ulepszania nakierowania na komórki nowotworowe z ekspresją CD138
AU2013201618B2 (en) * 2009-05-06 2016-06-02 Biotest Ag Uses of immunoconjugates targeting CD138
AU2010244428B2 (en) 2009-05-06 2015-01-29 Biotest Ag Uses of immunoconjugates targeting CD138
EP2589609A1 (en) 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
EP2788030B1 (en) 2011-12-08 2018-06-20 Biotest AG Uses of immunoconjugates targeting cd138
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
EP3456818B1 (en) * 2013-03-07 2020-05-20 Baylor College of Medicine Targeting cd138 in cancer
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
CA3131724A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Anti-cd3 antibodies and methods of use
ES2785551T3 (es) 2014-06-30 2020-10-07 Glykos Finland Oy Derivado de sacárido de una carga útil tóxica y sus conjugados con anticuerpos
EP3307282A4 (en) * 2015-06-12 2019-05-01 Immunomedics, Inc. DISEASE THERAPY WITH CONSTRUCTS OF CHIMERIC ANTIGEN RECEPTOR (CAR) AND T-CELL (CAR-T) OR NK-CELL (CAR-NK) EXPRESSIVE CAR CONSTRUCTS
KR20250021639A (ko) 2015-06-16 2025-02-13 제넨테크, 인크. FcRH5에 대한 인간화 및 친화도 성숙 항체 및 사용방법
CN107849145B (zh) 2015-06-16 2021-10-26 基因泰克公司 抗cd3抗体及其使用方法
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
KR20190074300A (ko) 2016-11-15 2019-06-27 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
CN110234348B (zh) 2016-12-16 2024-06-25 蓝鳍生物医药公司 抗-含cub结构域蛋白1(cdcp1)抗体、抗体药物缀合物及其使用方法
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
EP3692069A1 (en) 2017-10-02 2020-08-12 Visterra, Inc. Antibody molecules to cd138 and uses thereof
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
KR20200118065A (ko) 2018-02-08 2020-10-14 제넨테크, 인크. 이중특이적 항원-결합 분자 및 이의 사용 방법
SG11202110702WA (en) * 2019-04-29 2021-11-29 Immunogen Inc Therapeutic combinations comprising anti-cd123 immunoconjugates
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
KR20220044939A (ko) 2019-06-17 2022-04-12 비스테라, 인크. Cd138에 대한 인간화 항체 분자 및 이의 용도
CR20220330A (es) 2019-12-13 2022-08-04 Genentech Inc Anticuerpos anti-ly6g6d y métodos de uso.
TWI874719B (zh) 2020-11-04 2025-03-01 美商建南德克公司 用抗cd20/抗cd3雙特異性抗體進行治療之給藥
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
US12291575B2 (en) 2021-05-14 2025-05-06 Genentech, Inc. Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
WO2023201291A1 (en) 2022-04-13 2023-10-19 Genentech, Inc. Pharmaceutical compositions of mosunetuzumab and methods of use
GB202313214D0 (en) * 2023-08-30 2023-10-11 Iksuda Therapeutics Ltd Co-administration of antibody-drug conjugate

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) * 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) * 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4169888A (en) * 1977-10-17 1979-10-02 The Upjohn Company Composition of matter and process
US4137230A (en) * 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4307016A (en) * 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) * 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) * 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) * 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS5566585A (en) * 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) * 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) * 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) * 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) * 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) * 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) * 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) * 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) * 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) * 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
US4444887A (en) * 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
WO1982001188A1 (en) * 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4315929A (en) * 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) * 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) * 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4761111A (en) * 1981-09-18 1988-08-02 Brown Andrew M Automobile lifting and towing equipment
US4418064A (en) * 1982-09-29 1983-11-29 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids: treflorine, trenudine, and N-methyltrenudone
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988002594A2 (en) 1986-10-09 1988-04-21 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US5034223A (en) * 1986-10-09 1991-07-23 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US5053394A (en) * 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5612016A (en) 1988-04-01 1997-03-18 Immunomedics, Inc. Conjugates of antibodies and bifunctional ligands
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
EP0527189A1 (en) * 1990-04-25 1993-02-17 PHARMACIA & UPJOHN COMPANY Novel cc-1065 analogs
US5814318A (en) * 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5998656A (en) * 1991-09-23 1999-12-07 Florida State University C10 tricyclic taxanes
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6080777A (en) * 1992-01-31 2000-06-27 The Trustees Of Columbia University In The City Of New York Taxol as a radiation sensitizer
US5200534A (en) * 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
CA2076465C (en) * 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
US6005079A (en) * 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5703247A (en) * 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
US5475011A (en) * 1993-03-26 1995-12-12 The Research Foundation Of State University Of New York Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment
US6740734B1 (en) * 1994-01-14 2004-05-25 Biovitrum Ab Bacterial receptor structures
SE9400088D0 (sv) * 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5763477A (en) * 1994-07-22 1998-06-09 Dr. Reddy's Research Foundation Taxane derivatives from 14-β-hydroxy-10 deacetylbaccatin III
CA2214993A1 (en) * 1995-03-10 1996-09-19 Qun Y. Zheng Cephalomannine epoxide, its analogues and a method for preparing the same
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5714586A (en) * 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
ES2172149T3 (es) 1997-04-14 2002-09-16 Micromet Ag Nuevo metodo para la produccion de receptores de antigeno anti-humano y sus usos.
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
DK1242401T3 (da) * 1999-11-24 2007-05-07 Immunogen Inc Cytotoksiske midler, der omfatter taxaner, og den terapeutiske anvendelse deraf
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
CA2455365C (en) * 2001-08-03 2014-07-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US6716821B2 (en) * 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US6534660B1 (en) * 2002-04-05 2003-03-18 Immunogen, Inc. CC-1065 analog synthesis
US6756397B2 (en) * 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
WO2003090781A1 (en) * 2002-04-23 2003-11-06 Meir Strahilevitz Methods and devices for targeting a site in a mammal and for removing species from a mammal
SG165158A1 (en) * 2002-05-02 2010-10-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
US6596757B1 (en) * 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
US7390898B2 (en) * 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US20040126379A1 (en) * 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
EP1587921B1 (en) * 2003-01-22 2010-07-28 GlycArt Biotechnology AG Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
US7449303B2 (en) 2003-05-02 2008-11-11 Health Research, Inc. Use of JAG2 expression in diagnosis of plasma cell disorders
US7276497B2 (en) * 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
CN103554261B (zh) * 2003-07-21 2017-03-01 伊缪诺金公司 Ca6抗原特异性细胞毒性偶联物及其应用方法
BRPI0510883B8 (pt) * 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
AU2004224925C1 (en) * 2004-08-30 2011-07-21 Biotest Ag Immunoconjugates targeting syndecan-1 expressing cells and use thereof
IL316252A (en) 2005-03-23 2024-12-01 Genmab As Antibodies against cd38 for treatment of multiple myeloma
KR20070120156A (ko) * 2005-04-15 2007-12-21 이뮤노젠 아이엔씨 종양에서 이종 또는 혼성 세포 집단의 제거 방법
TW200738750A (en) * 2005-12-06 2007-10-16 Domantis Ltd Ligands and methods of use therefor
EP2015772A2 (de) 2006-05-03 2009-01-21 Elke Pogge Von Strandmann Mittel zur behandlung von malignen erkrankungen

Similar Documents

Publication Publication Date Title
JP2011507933A5 (enExample)
Wang et al. Biomedical metal–organic framework materials: perspectives and challenges
AU2021282425B2 (en) Bioorthogonal compositions
Li et al. Nanomedicine embraces cancer radio-immunotherapy: mechanism, design, recent advances, and clinical translation
US11730765B2 (en) Platelet compositions and methods for the delivery of therapeutic agents
JP2005535606A5 (enExample)
JP2021175754A (ja) がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ−１抗体の組合せ
Wu et al. Hepatocellular carcinoma-targeted nanoparticles for cancer therapy
Li et al. PD-L1-targeted microbubbles loaded with docetaxel produce a synergistic effect for the treatment of lung cancer under ultrasound irradiation
JP2012517987A5 (ja) 吸入用の医薬組成物のｆｐｄ特性を設定する方法
JP2018035162A5 (enExample)
JP2016537380A5 (enExample)
JP2011505371A5 (enExample)
Hunt Precision targeting of intraperitoneal tumors with peptideguided nanocarriers
JP2015515974A5 (enExample)
CN101537015B (zh) 碳纳米管在制备抗肿瘤免疫治疗药物的免疫促进剂中的应用
US20250049936A1 (en) Bioorthogonal compositions
Tiersten et al. Phase I/II study of tandem cycles of high-dose chemotherapy followed by autologous hematopoietic stem cell support in women with advanced ovarian cancer
RU2465924C2 (ru) Способ лечения рака молочной железы
JP2010521488A5 (enExample)
Kamboj et al. A Transdermal Drug Delivery System for the Treatment of Cancer
Moorthy et al. Beyond borders: engineering organ-targeted immunotherapies to overcome site-specific barriers in cancer
KR20210106197A (ko) EGFR과 Her2 발현 암세포를 타겟으로 하는 항체-약물 중합체 개발
Nahar et al. Tenofovir Cons the Kidneys: A Case of Acquired Fanconi
CN1953784A (zh) 7－叔丁氧亚氨基甲基喜树碱用于治疗子宫肿瘤的用途